Gilmore Neil O'Neill - 03 Jun 2025 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
CEO, Director
Signature
/s/ Gilmore O'Neill
Issuer symbol
EDIT
Transactions as of
03 Jun 2025
Net transactions value
-$26,196
Form type
4
Filing time
04 Jun 2025, 18:36:39 UTC
Previous filing
27 Mar 2025
Next filing
04 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
O'Neill Gilmore Neil CEO, Director C/O EDITAS MEDICINE, INC., 11 HURLEY ST., CAMBRIDGE /s/ Gilmore O'Neill 04 Jun 2025 0001742084

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Sale $26,196 -15,192 -5.1% $1.72 280,282 03 Jun 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $1.7239 to $1.7566 . The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.